Next Article in Journal
New Insights into the Modification of the Non-Core Metabolic Pathway of Steroids in Mycolicibacterium and the Application of Fermentation Biotechnology in C-19 Steroid Production
Next Article in Special Issue
Berberine Induces Combined Cell Death in Gastrointestinal Cell Lines
Previous Article in Journal
The Phaseolus vulgaris Receptor-Like Kinase PvFER1 and the Small Peptides PvRALF1 and PvRALF6 Regulate Nodule Number as a Function of Nitrate Availability
Previous Article in Special Issue
Genistein and Procyanidin B2 Reduce Carcinogen-Induced Reactive Oxygen Species and DNA Damage through the Activation of Nrf2/ARE Cell Signaling in Bronchial Epithelial Cells In Vitro
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 6
10.3390/ijms24065235
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

A Sulfur Containing Melanogenesis Substrate, N-Pr-4-S-CAP as a Potential Source for Selective Chemoimmunotherapy of Malignant Melanoma

Int. J. Mol. Sci. 2023, 24(6), 5235; https://doi.org/10.3390/ijms24065235
by Yasuaki Tamura 1,*, Akira Ito 2, Kazumasa Wakamatsu 3, Toshihiko Torigoe 1, Hiroyuki Honda 4, Shosuke Ito 3 and Kowichi Jimbow 5
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2023, 24(6), 5235; https://doi.org/10.3390/ijms24065235
Submission received: 10 February 2023 / Revised: 4 March 2023 / Accepted: 6 March 2023 / Published: 9 March 2023
(This article belongs to the Special Issue Cancer Targeted Small Molecules)

Round 1

Reviewer 1 Report

In the manuscript the authors presented their finding, that intratumoral injection of N-Pr-4-S-CAP in combination with bone marrow derived dendritic cells had a powerful antitumor effect and induced very strong antimelanoma immunity mediated by cytotoxic T cells. They showed that DC take up N-Pr-4-S-CAP-treated B16-OVA melanoma cells and stimulate antigen specific CD8 T cells.  Taken together, the authors conclusively demonstrated, that N-Pr-4-S-CAP administration can be a new immunotherapeutic approach against melanoma. This is a relevant paper that can be accepted in the current form.

Author Response

Thakn you very much for reviewing our manuscript and we are grateful for your comments and decision.

Reviewer 2 Report

Congratulations to the authors for their work.
A suggestion for the future would be to expand their molecular study to determine if N-Pr-4-S-CAP inhibits all melanoma cells, regardless of the presence of genetic mutations.

Author Response

Thank you very much for reviewing our manuscript and giving us an important suggestion. We agree with your comment. We are planning to compare the effect of N-Pr-4-S-CAP using humaan melanoma cell lines with/without BRAF V600E mutation.  

Back to TopTop